A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.
Kratz
F
F
Tumor Biology Center, Department of Medical Oncology, Clinical Research, Breisacher Strasse 117, 79106 Freiburg, Federal Republic of Germany. felix@tumorbio.uni-freiburg.de
Müller-Driver
R
R
Hofmann
I
I
Drevs
J
J
Unger
C
C
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D003545:Cysteine / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*
D000970:Antineoplastic Agents; D006835:Hydrazones; D011355:Prodrugs; D012709:Serum Albumin; C461179:doxorubicin 4-(maleimid-1-yl)phenylacetylhydrazone; D004317:Doxorubicin; D003545:Cysteine